Roquefort Therapeutics (LON:ROQ) Trading Up 16.1% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s share price rose 16.1% during mid-day trading on Monday . The stock traded as high as GBX 2.10 ($0.03) and last traded at GBX 2.09 ($0.03). Approximately 5,286,537 shares traded hands during trading, an increase of 71% from the average daily volume of 3,088,488 shares. The stock had previously closed at GBX 1.80 ($0.02).

Roquefort Therapeutics Price Performance

The company’s 50 day simple moving average is GBX 2.80 and its 200 day simple moving average is GBX 3.60. The stock has a market capitalization of £2.93 million, a PE ratio of -1.90 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

Insider Activity at Roquefort Therapeutics

In related news, insider Stephen Paul West bought 400,000 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were acquired at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,511.89). Company insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.